0 XP   0   0   0

BRAIN Biotech AG
Buy, Hold or Sell?

Should you buy, hold or sell BRAIN Biotech AG?

I guess you are interested in BRAIN Biotech AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse BRAIN Biotech AG

Let's start. I'm going to help you getting a better view of BRAIN Biotech AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is BRAIN Biotech AG even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how BRAIN Biotech AG is doing in the market. If the company is worth buying. The latest step is to find out how other investors value BRAIN Biotech AG. The closing price on 2023-01-31 was €6.2 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
BRAIN Biotech AG Daily Candlestick Chart
BRAIN Biotech AG Daily Candlestick Chart
Summary









1. Valuation of BRAIN Biotech AG




Current price per share

€6.20

2. Growth of BRAIN Biotech AG




Is BRAIN Biotech AG growing?

Current yearPrevious yearGrowGrow %
How rich?$45.3m$28.3m$17m37.5%

How much money is BRAIN Biotech AG making?

Current yearPrevious yearGrowGrow %
Making money-$5.3m-$10.5m$5.1m94.8%
Net Profit Margin-13.0%-25.3%--

How much money comes from the company's main activities?

3. Financial Health of BRAIN Biotech AG




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#704 / 1232

Most Revenue
#227 / 1232

Most Profit
#439 / 1232

Most Efficient
#633 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of BRAIN Biotech AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BRAIN Biotech AG earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • A Net Profit Margin of -13.0% means that €-0.13 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BRAIN Biotech AG:

  • The MRQ is -13.0%. The company is making a huge loss. -2
  • The TTM is -13.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-13.0%TTM-13.0%0.0%
TTM-13.0%YOY-25.3%+12.4%
TTM-13.0%5Y-27.0%+14.1%
5Y-27.0%10Y-33.2%+6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.0%-223.6%+210.6%
TTM-13.0%-281.7%+268.7%
YOY-25.3%-344.8%+319.5%
5Y-27.0%-450.1%+423.1%
10Y-33.2%-541.0%+507.8%
1.1.2. Return on Assets

Shows how efficient BRAIN Biotech AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • -6.4% Return on Assets means that BRAIN Biotech AG generated €-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BRAIN Biotech AG:

  • The MRQ is -6.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.4%TTM-6.4%0.0%
TTM-6.4%YOY-13.4%+7.0%
TTM-6.4%5Y-12.1%+5.7%
5Y-12.1%10Y-16.3%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.4%-9.9%+3.5%
TTM-6.4%-8.9%+2.5%
YOY-13.4%-9.3%-4.1%
5Y-12.1%-11.7%-0.4%
10Y-16.3%-12.7%-3.6%
1.1.3. Return on Equity

Shows how efficient BRAIN Biotech AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • -12.8% Return on Equity means BRAIN Biotech AG generated €-0.13 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BRAIN Biotech AG:

  • The MRQ is -12.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.8%TTM-12.8%0.0%
TTM-12.8%YOY-46.6%+33.8%
TTM-12.8%5Y-39.3%+26.5%
5Y-39.3%10Y-49.7%+10.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.8%-12.0%-0.8%
TTM-12.8%-11.5%-1.3%
YOY-46.6%-10.8%-35.8%
5Y-39.3%-14.2%-25.1%
10Y-49.7%-15.2%-34.5%

1.2. Operating Efficiency of BRAIN Biotech AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BRAIN Biotech AG is operating .

  • Measures how much profit BRAIN Biotech AG makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • An Operating Margin of -11.3% means the company generated €-0.11  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BRAIN Biotech AG:

  • The MRQ is -11.3%. The company is operating very inefficient. -2
  • The TTM is -11.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-11.3%TTM-11.3%0.0%
TTM-11.3%YOY-26.7%+15.5%
TTM-11.3%5Y-26.5%+15.3%
5Y-26.5%10Y-31.9%+5.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.3%-207.3%+196.0%
TTM-11.3%-271.0%+259.7%
YOY-26.7%-325.9%+299.2%
5Y-26.5%-454.0%+427.5%
10Y-31.9%-537.1%+505.2%
1.2.2. Operating Ratio

Measures how efficient BRAIN Biotech AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.20 means that the operating costs are €1.20 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BRAIN Biotech AG:

  • The MRQ is 1.204. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.204. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.204TTM1.2040.000
TTM1.204YOY1.209-0.005
TTM1.2045Y1.264-0.060
5Y1.26410Y1.368-0.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2042.871-1.667
TTM1.2043.504-2.300
YOY1.2093.604-2.395
5Y1.2645.132-3.868
10Y1.3686.371-5.003

1.3. Liquidity of BRAIN Biotech AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.45 means the company has €3.45 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BRAIN Biotech AG:

  • The MRQ is 3.451. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.451. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.451TTM3.4510.000
TTM3.451YOY2.677+0.773
TTM3.4515Y3.661-0.210
5Y3.66110Y3.203+0.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4515.117-1.666
TTM3.4515.755-2.304
YOY2.6775.854-3.177
5Y3.6616.511-2.850
10Y3.2036.222-3.019
1.3.2. Quick Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • A Quick Ratio of 2.80 means the company can pay off €2.80 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BRAIN Biotech AG:

  • The MRQ is 2.797. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.797. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.797TTM2.7970.000
TTM2.797YOY2.081+0.716
TTM2.7975Y2.963-0.166
5Y2.96310Y2.477+0.486
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7974.284-1.487
TTM2.7974.664-1.867
YOY2.0814.787-2.706
5Y2.9635.218-2.255
10Y2.4775.182-2.705

1.4. Solvency of BRAIN Biotech AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BRAIN Biotech AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BRAIN Biotech AG to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that BRAIN Biotech AG assets are financed with 46.2% credit (debt) and the remaining percentage (100% - 46.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.462. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.462. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.462TTM0.4620.000
TTM0.462YOY0.638-0.176
TTM0.4625Y0.548-0.086
5Y0.54810Y0.554-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4620.278+0.184
TTM0.4620.277+0.185
YOY0.6380.306+0.332
5Y0.5480.367+0.181
10Y0.5540.403+0.151
1.4.2. Debt to Equity Ratio

Measures if BRAIN Biotech AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • A Debt to Equity ratio of 92.6% means that company has €0.93 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.926. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.926. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.926TTM0.9260.000
TTM0.926YOY2.213-1.288
TTM0.9265Y1.859-0.933
5Y1.85910Y1.938-0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9260.315+0.611
TTM0.9260.317+0.609
YOY2.2130.319+1.894
5Y1.8590.403+1.456
10Y1.9380.462+1.476

2. Market Valuation of BRAIN Biotech AG

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings BRAIN Biotech AG generates.

  • Above 15 is considered overpriced but always compare BRAIN Biotech AG to the Biotechnology industry mean.
  • A PE ratio of -44.38 means the investor is paying €-44.38 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BRAIN Biotech AG:

  • The EOD is -27.243. Company is losing money. -2
  • The MRQ is -44.380. Company is losing money. -2
  • The TTM is -44.380. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-27.243MRQ-44.380+17.137
MRQ-44.380TTM-44.3800.000
TTM-44.380YOY-16.018-28.363
TTM-44.3805Y-35.525-8.856
5Y-35.52510Y-24.378-11.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.243-8.986-18.257
MRQ-44.380-9.792-34.588
TTM-44.380-16.243-28.137
YOY-16.018-20.876+4.858
5Y-35.525-16.665-18.860
10Y-24.378-14.732-9.646
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of BRAIN Biotech AG.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of BRAIN Biotech AG:

  • The MRQ is -29.854. Very Bad. -2
  • The TTM is -29.854. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-29.854TTM-29.8540.000
TTM-29.854YOY-14.206-15.648
TTM-29.8545Y-31.663+1.809
5Y-31.66310Y-21.303-10.360
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.854-0.032-29.822
TTM-29.8540.004-29.858
YOY-14.2060.016-14.222
5Y-31.6630.006-31.669
10Y-21.3030.003-21.306

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BRAIN Biotech AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.28 means the investor is paying €5.28 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BRAIN Biotech AG:

  • The EOD is 3.238. Neutral. Compare to industry.
  • The MRQ is 5.276. Seems overpriced? -1
  • The TTM is 5.276. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD3.238MRQ5.276-2.037
MRQ5.276TTM5.2760.000
TTM5.276YOY5.933-0.658
TTM5.2765Y9.646-4.371
5Y9.64610Y7.216+2.431
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2381.835+1.403
MRQ5.2762.006+3.270
TTM5.2762.774+2.502
YOY5.9333.453+2.480
5Y9.6462.713+6.933
10Y7.2162.402+4.814
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BRAIN Biotech AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7180.7180%0.414+73%0.136+426%0.239+200%
Book Value Growth--1.6001.6000%1.530+5%1.219+31%1.598+0%
Book Value Per Share--1.9141.9140%1.197+60%1.493+28%1.199+60%
Book Value Per Share Growth--1.6001.6000%1.530+5%1.219+31%1.598+0%
Current Ratio--3.4513.4510%2.677+29%3.661-6%3.203+8%
Debt To Asset Ratio--0.4620.4620%0.638-28%0.548-16%0.554-17%
Debt To Equity Ratio--0.9260.9260%2.213-58%1.859-50%1.938-52%
Dividend Per Share----0%-0%-0%-0%
Eps---0.228-0.2280%-0.443+95%-0.396+74%-0.393+73%
Eps Growth--1.4871.4870%1.128+32%1.147+30%0.861+73%
Free Cash Flow Per Share---0.237-0.2370%-0.349+48%-0.335+42%-0.318+34%
Free Cash Flow Per Share Growth--1.3221.3220%1.239+7%1.082+22%0.891+48%
Free Cash Flow To Equity Per Share--0.2930.2930%0.250+17%0.184+59%0.173+70%
Free Cash Flow To Equity Per Share Growth--1.1711.1710%2.531-54%0.489+140%2.576-55%
Gross Profit Margin--1.2761.2760%1.163+10%1.214+5%1.178+8%
Intrinsic Value_10Y_max---2.552--------
Intrinsic Value_10Y_min---2.182--------
Intrinsic Value_1Y_max---0.241--------
Intrinsic Value_1Y_min---0.234--------
Intrinsic Value_3Y_max---0.736--------
Intrinsic Value_3Y_min---0.695--------
Intrinsic Value_5Y_max---1.244--------
Intrinsic Value_5Y_min---1.141--------
Net Profit Margin---0.130-0.1300%-0.253+96%-0.270+109%-0.332+156%
Operating Margin---0.113-0.1130%-0.267+137%-0.265+135%-0.319+183%
Operating Ratio--1.2041.2040%1.2090%1.264-5%1.368-12%
Pb Ratio3.238-63%5.2765.2760%5.933-11%9.646-45%7.216-27%
Pe Ratio-27.243+39%-44.380-44.3800%-16.018-64%-35.525-20%-24.378-45%
Peg Ratio---29.854-29.8540%-14.206-52%-31.663+6%-21.303-29%
Price Per Share6.200-63%10.10010.1000%7.100+42%13.316-24%9.785+3%
Price To Total Gains Ratio8.636-63%14.06914.0690%17.138-18%1.965+616%3.650+285%
Profit Growth--1.4871.4870%1.076+38%1.154+29%0.867+72%
Quick Ratio--2.7972.7970%2.081+34%2.963-6%2.477+13%
Return On Assets---0.064-0.0640%-0.134+110%-0.121+89%-0.163+155%
Return On Equity---0.128-0.1280%-0.466+263%-0.393+207%-0.497+288%
Revenue Growth--1.0041.0040%0.991+1%1.120-10%1.187-15%
Total Gains Per Share--0.7180.7180%0.414+73%0.136+426%0.239+200%
Total Gains Per Share Growth--1.7331.7330%2.668-35%1.148+51%1.396+24%
Usd Book Value--45390660.40045390660.4000%28370383.600+60%35391193.520+28%28431115.733+60%
Usd Book Value Change Per Share--0.7790.7790%0.450+73%0.148+426%0.260+200%
Usd Book Value Per Share--2.0782.0780%1.299+60%1.620+28%1.301+60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.247-0.2470%-0.481+95%-0.430+74%-0.427+73%
Usd Free Cash Flow---5608313.600-5608313.6000%-8275735.200+48%-7938672.080+42%-6944785.420+24%
Usd Free Cash Flow Per Share---0.257-0.2570%-0.379+48%-0.363+42%-0.345+34%
Usd Free Cash Flow To Equity Per Share--0.3180.3180%0.272+17%0.200+59%0.187+70%
Usd Price Per Share6.728-63%10.96110.9610%7.705+42%14.451-24%10.619+3%
Usd Profit---5395614.400-5395614.4000%-10509076.800+95%-9287575.680+72%-9256872.523+72%
Usd Revenue--41659742.80041659742.8000%41481770.000+0%36100263.200+15%30282495.284+38%
Usd Total Gains Per Share--0.7790.7790%0.450+73%0.148+426%0.260+200%
 EOD+2 -3MRQTTM+0 -0YOY+36 -45Y+35 -510Y+37 -3

3.2. Fundamental Score

Let's check the fundamental score of BRAIN Biotech AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-27.243
Price to Book Ratio (EOD)Between0-13.238
Net Profit Margin (MRQ)Greater than0-0.130
Operating Margin (MRQ)Greater than0-0.113
Quick Ratio (MRQ)Greater than12.797
Current Ratio (MRQ)Greater than13.451
Debt to Asset Ratio (MRQ)Less than10.462
Debt to Equity Ratio (MRQ)Less than10.926
Return on Equity (MRQ)Greater than0.15-0.128
Return on Assets (MRQ)Greater than0.05-0.064
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of BRAIN Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.965
Ma 20Greater thanMa 506.193
Ma 50Greater thanMa 1006.041
Ma 100Greater thanMa 2005.717
OpenGreater thanClose6.160
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2017-09-302018-09-302019-09-302020-09-302021-09-30
Minority Interest  1824,7024,884-274,8575015,358-5,650-292



Latest Balance Sheet

Balance Sheet of 2021-09-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets77,737
Total Liabilities35,910
Total Stockholder Equity38,783
 As reported
Total Liabilities 35,910
Total Stockholder Equity+ 38,783
Total Assets = 77,737

Assets

Total Assets77,737
Total Current Assets39,114
Long-term Assets39,114
Total Current Assets
Cash And Cash Equivalents 24,545
Short-term Investments 105
Net Receivables 6,953
Other Current Assets 7,453
Total Current Assets  (as reported)39,114
Total Current Assets  (calculated)39,056
+/- 58
Long-term Assets
Property Plant Equipment 24,291
Goodwill 4,725
Intangible Assets 8,806
Long-term Assets Other 356
Long-term Assets  (as reported)38,623
Long-term Assets  (calculated)38,178
+/- 445

Liabilities & Shareholders' Equity

Total Current Liabilities11,335
Long-term Liabilities24,575
Total Stockholder Equity38,783
Total Current Liabilities
Short-term Debt 2,643
Short Long Term Debt 1,567
Accounts payable 3,831
Other Current Liabilities 4,319
Total Current Liabilities  (as reported)11,335
Total Current Liabilities  (calculated)12,360
+/- 1,025
Long-term Liabilities
Long term Debt Total 9,060
Other Liabilities 15,515
Deferred Long Term Liability 86
Long-term Liabilities  (as reported)24,575
Long-term Liabilities  (calculated)24,661
+/- 86
Total Stockholder Equity
Common Stock21,847
Retained Earnings -79,509
Capital Surplus 95,890
Total Stockholder Equity (as reported)38,783
Total Stockholder Equity (calculated)38,228
+/- 555
Other
Capital Stock21,847
Cash And Equivalents24,545
Cash and Short Term Investments 24,650
Common Stock Shares Outstanding 19,943
Liabilities and Stockholders Equity 74,693
Net Debt -21,902
Net Invested Capital 40,350
Net Tangible Assets 25,252
Net Working Capital 27,779
Short Long Term Debt Total 2,643



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-09-302020-09-302019-09-302018-09-302017-09-302016-09-302015-09-302014-09-30
> Total Assets 
25,072
30,407
47,512
68,504
74,464
66,124
72,150
77,737
77,73772,15066,12474,46468,50447,51230,40725,072
   > Total Current Assets 
12,163
15,071
32,001
53,557
41,016
30,957
33,083
39,114
39,11433,08330,95741,01653,55732,00115,07112,163
       Cash And Cash Equivalents 
4,459
3,180
8,261
38,954
25,539
15,160
18,943
24,545
24,54518,94315,16025,53938,9548,2613,1804,459
       Short-term Investments 
0
300
10,400
86
260
63
103
105
105103632608610,4003000
       Net Receivables 
2,952
4,443
6,143
6,844
6,585
7,102
6,566
6,953
6,9536,5667,1026,5856,8446,1434,4432,952
       Inventory 
4,569
6,516
7,123
7,189
8,033
7,926
6,964
7,011
7,0116,9647,9268,0337,1897,1236,5164,569
       Other Current Assets 
20
5,075
6,218
7,328
7,184
7,808
7,073
7,453
7,4537,0737,8087,1847,3286,2185,07520
   > Long-term Assets 
0
15,336
15,511
14,947
33,448
35,167
39,067
38,623
38,62339,06735,16733,44814,94715,51115,3360
       Property Plant Equipment 
6,881
6,878
7,095
7,590
12,042
17,144
24,469
24,291
24,29124,46917,14412,0427,5907,0956,8786,881
       Goodwill 
2,587
2,818
2,817
2,671
6,365
4,586
4,484
4,725
4,7254,4844,5866,3652,6712,8172,8182,587
       Long Term Investments 
159
0
168
166
1,984
1,438
0
0
001,4381,9841661680159
       Intangible Assets 
3,077
5,217
4,930
4,416
12,711
11,208
8,787
8,806
8,8068,78711,20812,7114,4164,9305,2173,077
       Long-term Assets Other 
0
448
10,558
190
606
854
433
356
35643385460619010,5584480
> Total Liabilities 
11,224
24,652
20,586
21,142
43,825
49,032
46,007
35,910
35,91046,00749,03243,82521,14220,58624,65211,224
   > Total Current Liabilities 
5,296
7,727
10,413
8,425
10,973
14,873
12,357
11,335
11,33512,35714,87310,9738,42510,4137,7275,296
       Short-term Debt 
1,872
2,106
3,449
1,514
2,442
3,603
3,277
2,643
2,6433,2773,6032,4421,5143,4492,1061,872
       Short Long Term Debt 
1,872
924
792
998
1,378
1,220
0
1,567
1,56701,2201,3789987929241,872
       Accounts payable 
1,351
3,082
2,862
2,433
2,872
4,428
3,171
3,831
3,8313,1714,4282,8722,4332,8623,0821,351
       Other Current Liabilities 
1,318
2,539
4,103
4,478
4,622
5,724
5,153
4,319
4,3195,1535,7244,6224,4784,1032,5391,318
   > Long-term Liabilities 
0
16,924
10,173
12,717
32,852
34,159
33,650
24,575
24,57533,65034,15932,85212,71710,17316,9240
       Long term Debt Total 
0
0
6,241
8,181
25,353
5,378
10,756
9,060
9,06010,7565,37825,3538,1816,24100
       Capital Lease Obligations 
0
0
0
0
0
0
0
1,076
1,0760000000
       Long-term Liabilities Other 
0
0
1,128
1,826
1,355
64
3
736
7363641,3551,8261,12800
       Deferred Long Term Liability 
0
46
82
70
251
216
113
86
861132162517082460
> Total Stockholder Equity
12,255
5,451
26,680
47,180
25,755
12,234
20,785
38,783
38,78320,78512,23425,75547,18026,6805,45112,255
   Common Stock
12,726
12,726
16,414
18,056
18,056
18,056
19,861
21,847
21,84719,86118,05618,05618,05616,41412,72612,726
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 0-10,436-8,838-7,918-6,935-6,225-5,6210
   Capital Surplus 
0
0
0
0
0
65,170
78,386
95,890
95,89078,38665,17000000
   Treasury Stock00000000
   Other Stockholders Equity 
0
21,785
54,620
83,795
71,406
73,664
88,857
96,445
96,44588,85773,66471,40683,79554,62021,7850



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-09-30)

Gross Profit (+$)
totalRevenue38,389
Cost of Revenue-16,819
Gross Profit21,57021,570
 
Operating Income (+$)
Gross Profit21,570
Operating Expense-29,402
Operating Income-7,832-7,832
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,347
Selling And Marketing Expenses1,371
Operating Expense29,4022,718
 
Net Interest Income (+$)
Interest Income11
Interest Expense-236
Net Interest Income3,300-225
 
Pretax Income (+$)
Operating Income-7,832
Net Interest Income3,300
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-4,276-11,388
EBIT - interestExpense = -4,569
-4,569
-4,736
Interest Expense236
Earnings Before Interest and Taxes (ebit)-4,333-4,040
Earnings Before Interest and Taxes (ebitda)-319
 
After tax Income (+$)
Income Before Tax-4,276
Tax Provision-403
Net Income From Continuing Ops-4,680-4,679
Net Income-4,972
Net Income Applicable To Common Shares-4,972
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses46,221
Total Other Income/Expenses Net3,556-3,300
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
VGE.AU
1 minute ago

I found you a Golden Cross on the daily chart of VGE.AU.

VGE.AU Daily Candlestick Chart
SVY.AU
24 minutes ago

I found you a Golden Cross on the daily chart of SVY.AU.

SVY.AU Daily Candlestick Chart
SPT.AU
28 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of SPT.AU.

SPT.AU Daily Candlestick Chart
SMP.AU
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SMP.AU.

SMP.AU Daily Candlestick Chart
SGP.AU
36 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGP.AU.

SGP.AU Daily Candlestick Chart
SDR.AU
38 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SDR.AU.

SDR.AU Daily Candlestick Chart
RMS.AU
43 minutes ago

I found you a Golden Cross on the daily chart of RMS.AU.

RMS.AU Daily Candlestick Chart
PLL.AU
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of PLL.AU.

PLL.AU Daily Candlestick Chart
PGD.AU
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of PGD.AU.

PGD.AU Daily Candlestick Chart
OML.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OML.AU.

OML.AU Daily Candlestick Chart
MVA.AU
1 hour ago

I found you a Golden Cross on the daily chart of MVA.AU.

MVA.AU Daily Candlestick Chart
BRX.AU
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of BRX.AU.

BRX.AU Daily Candlestick Chart
HTG.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HTG.AU.

HTG.AU Daily Candlestick Chart
SLB.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SLB.AU.

SLB.AU Daily Candlestick Chart
GLA.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GLA.AU.

GLA.AU Daily Candlestick Chart
ENX.AU
1 hour ago

I found you a Three Black Crows Candle Pattern on the daily chart of ENX.AU.

ENX.AU Daily Candlestick Chart
GLH.AU
1 hour ago

I found you a Rising Three Methods Candle Pattern on the daily chart of GLH.AU.

GLH.AU Daily Candlestick Chart
PLT.AU
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PLT.AU.

PLT.AU Daily Candlestick Chart
GRX.AU
1 hour ago

I found you a MACD Bullish Hidden Divergence on the daily chart of GRX.AU.

GRX.AU Daily Candlestick Chart
HVY.AU
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of HVY.AU.

HVY.AU Daily Candlestick Chart
BMG.AU
1 hour ago

I found you a RSI Bullish Reversal Divergence on the daily chart of BMG.AU.

BMG.AU Daily Candlestick Chart
EVZ.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EVZ.AU.

EVZ.AU Daily Candlestick Chart
ANX.AU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ANX.AU.

ANX.AU Daily Candlestick Chart
NGS.AU
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of NGS.AU.

NGS.AU Daily Candlestick Chart